Ultrasound Model to Help Differentiate Between Placenta Accreta Spectrum and Uterine Dehiscence in 3rd Trimester Pregnancies

November 14, 2025 updated by: Mostafa Ahmed Mohammed Refaat Askalany, Assiut University

Placenta Accreta Spectrum VS Uterine Scar Dehiscence: Accurate Ultrasound Model in 3rd Trimester Pregnancies for Percise Diagnosis

By using 2d Ultrasound on 3rd trimester pregnant women, a model is made to help differentiate between placenta accreta spectrum and uterine scar dehiscence before operative action to help prepare multi-disciplinary steps if needed

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

A cross-sectional observational study

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Female patients admitted to women health hospital, Assiut university, Assiut

Description

Inclusion Criteria:

  • Women in 3rd trimester pregnancy with low lying placenta previa
  • History of 1 or more C-section
  • Patients planning to deliver baby in Assiut women health hospital
  • Willing and able to participate

Exclusion Criteria:

  • Antepartum Hemorrhage(sever attack) as it hinders time for accurate diagnosis and calling expert team of diagnosis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: Placental site
Time Frame: (gestational age 28wk-full term) till operation
(gestational age 28wk-full term) till operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: placental thickness
Time Frame: (gestational age 28wk- full term) till operation
(gestational age 28wk- full term) till operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: placental size
Time Frame: (gestational age 28wk- fullterm) till operation
(gestational age 28wk- fullterm) till operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: placental lacunae
Time Frame: (gestational age 28wk-full term) till operation
(gestational age 28wk-full term) till operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: Loss of placental hypoechoic zone
Time Frame: (gestattional age 28wk-full term) till operation
(gestattional age 28wk-full term) till operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: Mean systolic velocity in both uterine arteries
Time Frame: (gestational age 28wks-full term) till time of operation
(gestational age 28wks-full term) till time of operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: Peak systolic velocity in uteroplacental interface
Time Frame: (gestational age 28wks- full term) till operation
(gestational age 28wks- full term) till operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: Peak systolic velocity in uterovesical interface
Time Frame: (gestational age 28wks- full term) ill operation
(gestational age 28wks- full term) ill operation

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Placental site
Time Frame: (gestational age 28wk- fullterm) till operation
(gestational age 28wk- fullterm) till operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Placental size
Time Frame: (gestational age 28wk- full term)till the operation
(gestational age 28wk- full term)till the operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Placental thickness
Time Frame: (gestational age 28wk-full term) till operation
(gestational age 28wk-full term) till operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Placental lacunae
Time Frame: (gestational age 28wk- fullterm) till operation
(gestational age 28wk- fullterm) till operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Loss of placental hypoechoic zone
Time Frame: (gestational age 28wks - fullterm) till operation
(gestational age 28wks - fullterm) till operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Mean systolic velocity in both uterine arteries
Time Frame: (gestational age 28wk- fullterm) till operation
(gestational age 28wk- fullterm) till operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Peak systolic velocity in uteroplacental interface
Time Frame: (gestational age 28wk- fullterm) till operation
(gestational age 28wk- fullterm) till operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Peak systolic velocity in uterovesical interface
Time Frame: (gestational age 28wk-full term) till operation
(gestational age 28wk-full term) till operation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Assiut University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 15, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 15, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 15, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 30, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 14, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 19, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 19, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 14, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 042025201333

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings